CAPT-ACTP 2020 Poster Presentation Gallery

CLICK HERE FOR THE ABSTRACT BOOKLET

CLICK HERE FOR A LIST OF POSTERS BY AUTHOR

POSTERS BY TITLE

#1: Non-Steroidal Anti-Inflammatory Drug Use Does Not Adhere To Prescribing Guidelines For Older Men Or Women With Dementia
#2: Psychiatric and non-psychiatric polypharmacy among older adults with schizophrenia: a population-based study in Quebec, Canada, between 2000 and 2016
#3: Polypharmacy among older adults in Quebec between 2000 and 2016
#4: Multimorbidity occurs 5 to 10 years sooner in highly deprived neighbourhoods
#5: Disease Activity Trajectories for Early and Established Rheumatoid Arthritis: Data from A Rheumatoid Arthritis Cohort
#6: Sociodemographic, Disease, and Medication Profile of RA Patients under 65 years Compared with 65 Years or Older at Registry Enrollment Data from A Rheumatoid Arthritis Cohort
#7: The impact of continuity of care on medication adherence
#8: Health Utilities Index Mark 3 Scores for Children: Population Norms for Canada Based on the 1994-95 National Longitudinal Survey of Children and Youth
#9: Public versus private payer perspective: Implications on cost-effectiveness
#10: Supporting Stability for Oncology Patients in a Time of Health System Instability: Creation of an Online Hub for Information, Mental Health and Wellness and Practical Supports
#12: Impact of Patented Medicine Prices Review Board new reference countries on drug prices in Canada: A comparison of current and anticipated list prices for top drugs in the country
#13: Comparing Academic and Community Practices in the Management of Rheumatoid Arthritis: Data from the OBRI Registry
#17: Can Canada’s patient support program infrastructure support the collection of real-world data for use in outcomes-based agreements?
#18: Over Half of Seniors Initiating Oral Bisphosphonates are Exposed for 3+ Years: Novel Rolling Window Approach & Patterns of Use
#19: Statin initiation: Guideline concordance and characteristics of new users in Quebec, Canada
#20: Access to zoledronic acid through the public drug plan for seniors in Ontario
#21: Utilization of hydroxychloroquine and azithromycin in Canada during the COVID 19 pandemic experience from a large Canadian private payer
#22: Reimbursement Recommendations of Conditionally-Approved Cancer Drugs in Canada
#23: Profiles of Opioid Consumption Associated with an Increased Risk of Acute Opioid-Related Healthcare Events
#25: The COVID-19 risk assessment model an interactive epidemiologic modelling platform
#26: Analysis of biosimilars private claims data in Canada
#27: Variability in Prescription Medication Coverage for Children and Youth across Canada A Scoping Review
#28: Development of an adapted operationalized definition of nudging for healthcare and medication optimization
#30: Pre-existing autoimmune disease and immune-related adverse events (irAE) with checkpoint inhibitors in melanoma
#31: Characteristics of a population exposed to a disease-modifying drug for multiple sclerosis in the real-world setting (1996-2017)
#32: Is treatment with sacubitril-valsartan compared to ACE inhibitors or ARBs more beneficial for women with heart failure?
#33: Persistence in Rheumatoid Arthritis Patients on Biosimilar and Bio-Originator Etanercept A Pooled Analysis of Pan-Canadian Cohorts
#35: Gender and authorship in pharmacoepidemiology studying the authorship patterns of Canadian Network for Observational Drug Effect Studies research
#36: Personalized comparisons of flare rates after hydroxychloroquine tapering or discontinuation in systemic lupus
#37: Using real world data to determine health system costs of Canadians diagnosed with chronic lymphocytic leukemia
#38: Retrospective cohort study of real world treatment patterns and overall survival in patients with chronic lymphocytic leukemia (CLL) diagnosed between 2010-2017 in Ontario, Canada
#39: Prevalence and characteristics of progressive fibrosing interstitial lung diseases
#40: Influence of drug safety advisories on drug utilization an international interrupted time series and meta-analysis study
#42: Report on the incompatibility of the proposed PMPRB guidelines with the perspective of patients/caregivers and the future of newlaunches of drugs for rare disease (DRDs) in Canada
#43: Impact of policy changes on utilization of community medication review services in Ontario among people living with diabetes
#44: Evaluation of the long-term cost-effectiveness of the Dexcom G6 continuous glucose monitor versus self-monitoring of blood glucose in people

Search for available posters by author last name below

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

Author Abstract Number

A
Abbas M 27
Abrahamowicz M 23, 30, 32, 36
Adebayo W 26
Ahmad A 27
Almeida-Brasil CC 36
Alobaid F 39
Andrew MK 1
Arthur E 22
Aw ATW 37, 38
Aydin S 13

B
Ball G 22
Bally M 19
Barber G 42
Behlouli H 32
Bergeron J 19
Bernatsky S 30, 33, 36
Binder L 10
Blackburn D 7
Blouin J 21
Boire G 33
Bombardier C 5, 6, 13
Bowles SK 1
Brown KJ 18
Burden AM 20
Burland E 35
Bykerk VP 33

C
Cadarette SM 18, 20, 43
Cesta A 5, 6, 13
Chan AW 30
Chan K 30
Chattha M 42
Cheung AM 18, 20
Choiniere M 19
Chong SG 39
Choquette D 33
Chow G 42
Clarke AE 36
Colmegna I 30
Coupal L 33
Cox G 39
Curtis JR 30

D
Dalseg C 17
De Jaray A 17
Dolovich L 28, 43
Dube M 3, 4, 19

E
Edwin JJ 37, 38
Elnoursi A 37, 38
Evans C 7, 31

F
Farooqi M 39
Feeny D 8
Fisk JD 31
Forte L 42
Forte M 42
Fortin PR 36

G
Gamble JM 43
Gaudet D 19
Gomes T 23
Gosselin E 3
Grootendorst P 20
Guertin JR 8

H
Hambly N 39
Hanly JG 36
Hassan S 37, 38
Hayes KN 18
He N 18, 20, 43
Helwig M 35
Henricks P 26
Hepworth E 13
Holbrook A 27, 28
Huang A 10
Hudson M 30
Humphries B 8, 26
Hurry M 37, 38

I
Isitt JJ 44

J
Jamal R 30
Jeffery W 42
Johnson SMA 19
Juurlink DN 18

K
Kim S 20
Kingwell E 31
Kirkland S 1
Kirwin E 25
Kolb M 39
Konstantelos N 20
Kurteva S 23

L
Lal A 21
Lamb-Palmer D 26
Lanctat H 19
Langevin C 12
Lavoie R 9
Lech R 42
Lee J 28
Lelorier J 19
Li X 5, 6
Lix L 7
Lu A 21
Lunghi C 2
Lynch P 44

M
Machado MAA 30
Maksymowych WP 33
Malmberg C 42
Mann K 42
Marino JP 22
Marrie RA 31
McCabe C 25
McCaffrey K 35
MacCallum L 43
Milenkovski R 22
Mintzes BJ 40
Miregwa B 27
Mirza R 13
Morrow RL 40
Moura CS 30, 33
Movahedi M 5, 6, 13

N
Ng HS 31

O
OReilly DJ 9
Ouali A 2

P
Penner N 21
Peschken CA 36
Peters R 28
Pilote L 30, 32
Pineau CA 36

R
Rafferty E 25
Rochette L 2
Round J 25
Roze S 44

S
Sakkat A 39
Scallan C 39
Scheider KAB 37, 38
Schieir O 33
Seung SJ 37, 38
Shakeri A 43
Simard M 3, 4
Sirois C 2, 3, 4
Sketris IS 35
Smith-Palmer J 44
Soares de Moura C 32
Sohani Z 32
Stewart SA 35
Svenson L 31
Sze F 17

T
Tamblyn R 23
Tardif JC 19
Tarride JE 8
Teare G 7
Tong R 10
Traynor RL 35
Tremlett H 31
Trenaman SC 1
Turnbull G 17

V
Valois MF 33
Vinet E 36

W
Walton RN 37, 38
Wills A 17
Wongkarnjama A 39

Y
Yao S 7

Z
Zhang J 28
Zhao Y 31
Zhu F 31
We are grateful to our CAPT-ACTP 2020 poster presentation sponsors: